Skip to main content
Program
#ScientificSessions26
Late-Breaking Science
Daily Coverage
Industry Highlights
Journeys
Search
Article
Company
Video
Daily Coverage
Industry Highlights
Journeys
Late-Breaking Science
Photo Gallery
Enter search phrase
Search
Section: Late-Breaking Science
AHA24
Coronary and valvular heart disease
Liberal or restrictive oxygenation, GLP-1 agonist therapy, edoxaban and spironolactone.
November 18, 2024
AHA24
Redefining arrhythmia treatment
Catheter ablation, OPTION and Brain-AF.
November 18, 2024
AHA24
Celebrating a century of cardiovascular science
Intensive blood pressure control, tirzepatide and novel gene editing therapy.
November 17, 2024
AHA24
Clinical Guideline Sessions
Get up to speed on all of the updates in guidelines.
October 24, 2024
Home
Late-Breaking Science for Sunday
Two presentations feature results from intervention and prevention studies.
October 23, 2024
Home
Featured Science for Saturday
Check out these featured studies.
October 23, 2024
Home
Don't miss today's Main Events
Six powerful Main Events to kick off your Scientific Sessions 2024.
October 23, 2024
Previews
#AHA24 Late-Breaking and Featured Science announced
See the impressive lineup of science planned for presentation at Scientific Sessions 2024.
September 30, 2024
AHA23
Late-breaking science| Achieving equity in prevention
Health care worker-led trial improves hypertension control, automated pharmacy referral for statin prescribing, SBP levels improving CVD outcomes and reducing hypertension in low-income population.
November 15, 2023
AHA23
Novel mechanisms for lipid-lowering therapy
Editing the PCSK9 gene, first-in-human trial of lepodisiran, new PCSK9 antibody and statins performance in people with HIV highlight four trials.
November 14, 2023
AHA23
Late-breaking science: AI at the bedside
AI-powered stethoscope, speech analysis for HF, interpreting ECGs with AI and prognostic tool for predicting MACE.
November 14, 2023
AHA23
Shocking decisions in AFib care
Trials’ results highlight the risks and benefits of oral anticoagulation, the superiority of dual direct cardioversion in patients with obesity and the potential for a novel factor XI inhibitor to reduce bleeding in patients with high risk of stroke.
November 13, 2023
AHA23
Drugs, diet and delivery can optimize hypertension outcomes
Findings evaluate dietary sodium reduction, postpartum blood pressure, an investigational RNA interference therapeutic agent and BP control and dementia risk.
November 13, 2023
AHA23
Heart failure late-breaking science
Trials highlight aspirin-free LVAD regimen, TEAMMATE and POCKET-COST-HF.
November 13, 2023
AHA23
Weight-loss drug reduced secondary CV risk in people with overweight or obesity without diabetes
November 12, 2023
AHA23
Trials’ results suggest new approaches to reducing CVD risk and symptoms
Three trials provide novel approaches to reduce CVD risk.
November 12, 2023
AHA23
Late-Breaking Science announced
See the impressive lineup of Late-Breaking Science on tap for presentation in Philadelphia.
September 21, 2023
AHA22
Early ablation bests medication in treatment naïve AFib patients
November 9, 2022
Previous Page
Next Page
